Gene Therapy Weekly: Verve's Trial Pause, Ginkgo's Acquisition, and FDA Decisions to Watch

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.In the latest edition of Gene Therapy Weekly, Verve pauses its base editing trial due to lab abnormalities in a study participant, prompting a shift in strategy. Ginkgo acquires another startup in search of more cell therapy tools, while Gritstone shares fall after shaky study results for a colorectal cancer vaccine. The newsletter highlights five FDA decisions to watch in the second quarter, including potential expansions for multiple myeloma cell therapies and a gene therapy medicine from Pfizer. Additionally, the newsletter features news on a scientist who gene-edited babies returning to work and a paralyzed man benefiting from stem cell therapy. Biopharma Dive's Gene Therapy Weekly covers a range of topics in biotech and pharma, from clinical trials to research partnerships, providing insights into the latest trends and news shaping the industry.